Table 2 of
Javadzadeh, Mol Vis 2013; 19:62-68. Table 2 of
Javadzadeh, Mol Vis 2013; 19:62-68.
Table 2. Laboratory parameters before and after Ca-D or placebo administration [mean±SD (median, interquartile range)].
| Laboratory parameters† | Group Ca-D | Group Placebo | P value | Group Ca-D | Group placebo | P value before | P value‡ after |
|---|---|---|---|---|---|---|---|
| FBS | 133.7±57.1(130,89.5–160.5) | 133±66.2 (105, 76.5–194.5) | 0.95 | 138.9±47.3 (144, 96–167.5) | 142.1±64.3(125,91.5–185) | 0.79 | 0.5 |
| Total cholesterol | 188.4±51.4(185,152–221.5) | 202.9±58.5 (192, 160–242.5) | 0.21 | 183.6±38.7(188,157.5–214) | 205.2±52.2(205,160–242.5) | 0.02* | 0.45 |
| HDL-C | 44±6.4 (44, 38–48) | 44.2±6.6 (44, 38–48) | 0.89 | 44.3±5.8 (44, 40–48) | 42.3±5.9(42,38.5–45) | 0.1 | 0.78 |
| LDL-C | 113.8±39.2(115,77–149) | 125.2±54.3 (111, 90.5–170) | 0.25 | 109±36.6 (113,77–130.5) | 125.6±47(115,89.5–148.5) | 0.06 | 0.32 |
| Triglyceride | 169.1±72.7(152, 119.5–213) | 193.4±110 (177, 116–220) | 0.46 | 161.2±61.6(160, 112–196) | 207.4±106.3(194, 135–275.5) | 0.01* | 0.29 |
| AST | 31.2±10.4(31,23–39.5) | 33.2±9.8 (33, 25.5–41) | 0.34 | 29.6±8.3(30,22.5–36.5) | 33.5±7.9 (34, 28–39) | 0.02* | 0.08 |
| ALT | 34.5±9.7 (32, 27–42) | 35.2±10.5 (35, 28–41) | 0.73 | 33.3±9 (32, 26.5–40) | 36.2±7.8(38,28–43.5) | 0.11 | 0.1 |
| Urea | 38.4±16.7(35,27–46.5) | 35.3±13 (34, 29.5–38) | 0.44 | 39.1±15.7 (35,30.5–45) | 40.8±19.7 (36,36–45) | 0.79 | 0.91 |
| Creatinine | 1.2±0.5 (1.1, 0.8–1.4) | 1.7±4.4 (1.1, 0.9–1.2) | 0.59 | 1.4±1.5 (1.1, 1–1.3) | 3.1±12.1 (1.2, 1–1.4) | 0.61 | 0.52 |
| Endothelin-1 | 0.8±0.2(0.83,0.7–1.01) | 0.7±0.3 (0.77, 0.48–0.95) | 0.1 | 0.6±0.3 (0.68,0.47–0.90) | 0.8±0.3 (0.9,0.64–1.09) | 0.01* | <0.001* |
| hsCRP | 5.6±6.9 (3.4, 1.3–7.5) | 3.8±3.6 (2.9, 1.3–5.1) | 0.44 | 3.2±3.2 (2.2, 0.85–4.15) | 4.6±3.7 (3.7, 1.95–5.95) | 0.01* | <0.001* |